Search results | adjuvant

Reports

Infectious Vaccines Partnering Terms and Agreements

The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals.

Vaccine Partnering Terms and Agreements

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

Cancer Vaccine Partnering Agreements

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Adjuvant

An adjuvant (from Latin, adiuvare: to aid) is a pharmacological or immunological agent

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Vaccine partnering

A vaccine is a biological preparation that improves immunity to a particular disease.

Infectives vaccine partnering

A vaccine is a biological preparation that improves immunity to a particular disease

Partnering with GlaxoSmithKline: Partners for innovation and success

GlaxoSmithKline is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and consumer healthcare

Partnering with Merck & Co: Combining our strengths, sharing our successes

Merck & Co is a top pharma company active in partnering, licensing and M&A in pharmaceuticals, consumer health and animal health

Industry trends in vaccine dealmaking – 2007 to 2013

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity

Events

Sorry, your search returned no results.


Deals

Research, development and licensing option agreement for combination of RSV antigen with NanoStat adjuvant technology

Preclinical collaboration with a subsidiary of Merck & Co focused on the development of a vaccine for Respiratory Syncytial Virus (RSV)

Idera and Merck extend research collaboration for agonists of toll-like receptors as vaccine adjuvants

In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease.

Big Biotech, Emergent Biosolutions signs a government contract for anthrax vaccine

Big biotech, Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases to develop a dry formulation of NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant).

Cerulean Pharma files for $75 milllion in IPO financing

Biotech company, Cerulean Pharma is pitching a $75 million IPO financing.

GSK pairs up in pharma partnering with Aeras to jointly advance TB vaccine

Aeras has signed a pharma partnering agreement with GlaxoSmithKline Vaccines, a top pharma company to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK’s proprietary M72 antigen and AS01E adjuvant

CureVac in Series D financing for $80 million

CureVac announced the completion of an 80 million financing round with its main investor, dievini Hopp BioTech Holding.

Bristol-Myers Squibb & Vical join fores in pharma licensing agreement

Bristol-Myers Squibb, a top 50 big pharma company entered into  a worldwide, nonexclusive pharma licensing partnership with Vical Incorporated of Vical’s patented platform DNA immunization technology and its Vaxfectin adjuvant for use in the production of antibodies.

Agenus expands QS-21 license and grants right of first negotiation to GlaxoSmithKline

Agenus announced that GlaxoSmithKline and Agenus have amended the QS-21 license and manufacturing agreement to include additional rights for the use of Agenus’ proprietary QS-21 Stimulon adjuvant in GSK Biologicals’ adjuvant systems

Nuron Biotech licenses HibTITER vaccine to Mitsubishi Tanabe for Japanese market

Nuron Biotech has licensed its HibTITER vaccine to Mitsubishi Tanabe Pharma for commercialization in the Japanese market for both the single entity and for combination product use. 

Pfizer receives backing for late-stage trial of kidney cancer drug in Asia

SFJ Pharma has entered into a collaborative development agreement with Pfizer to conduct a Phase 3 clinical trial in Asia of Pfizer’s investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.